Cargando…
Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
BACKGROUND: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622525/ https://www.ncbi.nlm.nih.gov/pubmed/28962610 http://dx.doi.org/10.1186/s12889-017-4776-8 |
_version_ | 1783267928013012992 |
---|---|
author | Haban, Houda Benchekroun, Soumia Sadeq, Mina Benjouad, Abdelaziz Amzazi, Said Oumzil, Hicham Elharti, Elmir |
author_facet | Haban, Houda Benchekroun, Soumia Sadeq, Mina Benjouad, Abdelaziz Amzazi, Said Oumzil, Hicham Elharti, Elmir |
author_sort | Haban, Houda |
collection | PubMed |
description | BACKGROUND: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country. METHODS: Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups. RESULTS: The median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response. CONCLUSION: In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children. |
format | Online Article Text |
id | pubmed-5622525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56225252017-10-11 Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco Haban, Houda Benchekroun, Soumia Sadeq, Mina Benjouad, Abdelaziz Amzazi, Said Oumzil, Hicham Elharti, Elmir BMC Public Health Research Article BACKGROUND: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country. METHODS: Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups. RESULTS: The median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response. CONCLUSION: In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children. BioMed Central 2017-09-29 /pmc/articles/PMC5622525/ /pubmed/28962610 http://dx.doi.org/10.1186/s12889-017-4776-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Haban, Houda Benchekroun, Soumia Sadeq, Mina Benjouad, Abdelaziz Amzazi, Said Oumzil, Hicham Elharti, Elmir Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco |
title | Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco |
title_full | Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco |
title_fullStr | Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco |
title_full_unstemmed | Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco |
title_short | Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco |
title_sort | assessment of the hbv vaccine response in a group of hiv-infected children in morocco |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622525/ https://www.ncbi.nlm.nih.gov/pubmed/28962610 http://dx.doi.org/10.1186/s12889-017-4776-8 |
work_keys_str_mv | AT habanhouda assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco AT benchekrounsoumia assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco AT sadeqmina assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco AT benjouadabdelaziz assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco AT amzazisaid assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco AT oumzilhicham assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco AT elhartielmir assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco |